177 related articles for article (PubMed ID: 37570646)
1. The Anticancer Effect of Napabucasin (BBI608), a Natural Naphthoquinone.
Shao Z; Wang H; Ren H; Sun Y; Chen X
Molecules; 2023 Jul; 28(15):. PubMed ID: 37570646
[TBL] [Abstract][Full Text] [Related]
2. Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death.
Froeling FEM; Swamynathan MM; Deschênes A; Chio IIC; Brosnan E; Yao MA; Alagesan P; Lucito M; Li J; Chang AY; Trotman LC; Belleau P; Park Y; Rogoff HA; Watson JD; Tuveson DA
Clin Cancer Res; 2019 Dec; 25(23):7162-7174. PubMed ID: 31527169
[TBL] [Abstract][Full Text] [Related]
3. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.
Hubbard JM; Grothey A
Drugs; 2017 Jul; 77(10):1091-1103. PubMed ID: 28573435
[TBL] [Abstract][Full Text] [Related]
4. Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells.
Han D; Yu T; Dong N; Wang B; Sun F; Jiang D
J Exp Clin Cancer Res; 2019 Jul; 38(1):289. PubMed ID: 31277685
[TBL] [Abstract][Full Text] [Related]
5. STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells.
Liu Y; Peng X; Li H; Jiao W; Peng X; Shao J; Xu Y; Wang R; Wang W; Kong D
Recent Pat Anticancer Drug Discov; 2021; 16(3):350-362. PubMed ID: 33655847
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Tumor Cell-Tumor Microenvironment Component Interactions as Potential Predictors of Patient Response to Napabucasin.
Chang AY; Hsu E; Patel J; Li Y; Zhang M; Iguchi H; Rogoff HA
Mol Cancer Res; 2019 Jul; 17(7):1429-1434. PubMed ID: 31043490
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
Thulin MH; Määttä J; Linder A; Sterbova S; Ohlsson C; Damber JE; Widmark A; Persson E
Prostate; 2021 Jun; 81(8):452-462. PubMed ID: 33822400
[TBL] [Abstract][Full Text] [Related]
8. The synergistic anticancer effects of ReoT3D, CPT-11, and BBI608 on murine colorectal cancer cells.
Babaei A; Soleimanjahi H; Soleimani M; Arefian E
Daru; 2020 Dec; 28(2):555-565. PubMed ID: 32803686
[TBL] [Abstract][Full Text] [Related]
9. Napabucasin, a novel inhibitor of STAT3, inhibits growth and synergises with doxorubicin in diffuse large B-cell lymphoma.
Li X; Wei Y; Wei X
Cancer Lett; 2020 Oct; 491():146-161. PubMed ID: 32798587
[TBL] [Abstract][Full Text] [Related]
10. Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
Löcken H; Clamor C; Müller K
J Nat Prod; 2018 Jul; 81(7):1636-1644. PubMed ID: 30003778
[TBL] [Abstract][Full Text] [Related]
11. A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).
Li C; Chen C; An Q; Yang T; Sang Z; Yang Y; Ju Y; Tong A; Luo Y
Eur J Med Chem; 2019 Jan; 162():543-554. PubMed ID: 30472602
[TBL] [Abstract][Full Text] [Related]
12. Molecular crosstalk between MUC1 and STAT3 influences the anti-proliferative effect of Napabucasin in epithelial cancers.
Bose M; Sanders A; Handa A; Vora A; Cardona MR; Brouwer C; Mukherjee P
Sci Rep; 2024 Feb; 14(1):3178. PubMed ID: 38326371
[TBL] [Abstract][Full Text] [Related]
13. Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage.
Bi S; Chen K; Feng L; Fu G; Yang Q; Deng M; Zhao H; Li Z; Yu L; Fang Z; Xu B
Eur J Pharmacol; 2019 Jul; 855():252-261. PubMed ID: 31085238
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells.
Zuo D; Shogren KL; Zang J; Jewison DE; Waletzki BE; Miller AL; Okuno SH; Cai Z; Yaszemski MJ; Maran A
J Exp Clin Cancer Res; 2018 Oct; 37(1):244. PubMed ID: 30286779
[TBL] [Abstract][Full Text] [Related]
15. Thermal Proteome Profiling in Zebrafish Reveals Effects of Napabucasin on Retinoic Acid Metabolism.
Leijten NM; Bakker P; Spaink HP; den Hertog J; Lemeer S
Mol Cell Proteomics; 2021; 20():100033. PubMed ID: 33594990
[TBL] [Abstract][Full Text] [Related]
16. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin.
Zhang Y; Jin Z; Zhou H; Ou X; Xu Y; Li H; Liu C; Li B
Cancer Med; 2016 Jun; 5(6):1251-8. PubMed ID: 26899963
[TBL] [Abstract][Full Text] [Related]
17. STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice.
Bitsch R; Kurzay A; Özbay Kurt F; De La Torre C; Lasser S; Lepper A; Siebenmorgen A; Müller V; Altevogt P; Utikal J; Umansky V
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35301236
[TBL] [Abstract][Full Text] [Related]
18. The cancer stemness inhibitor napabucasin suppresses small cell lung cancer growth through SOX2 expression.
Li JM; Hsu PC; Kuan FC; Shi CS; Yang CT
Am J Cancer Res; 2022; 12(10):4637-4651. PubMed ID: 36381330
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91.
Hanafi M; Chen X; Neamati N
J Med Chem; 2021 Feb; 64(3):1626-1648. PubMed ID: 33506674
[TBL] [Abstract][Full Text] [Related]
20. Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer.
Nagaraju GP; Farran B; Farren M; Chalikonda G; Wu C; Lesinski GB; El-Rayes BF
Cancer; 2020 Jul; 126(14):3360-3371. PubMed ID: 32383803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
